AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 43 min read$HSIC

Henry Schein (NASDAQ:HSIC) Surprises With Q2 CY2026 Sales

Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results with revenue up 6.7% year on year to $3.46 billion, exceeding Wall Street estimates by 2.6%, according to the company. Non-GAAP adjusted EPS was $1.27, up from $1.10, beating consensus by 2.5%. Adjusted operating margin was 5.3%. Analysts expect revenue growth of 2.9% over the next 12 months.

Original reporting
financialcontent.com
Published Aug 4, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:49 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Henry Schein (NASDAQ:HSIC) Surprises With Q2 CY2026 Sales — source image
Source · financialcontent.com
Decision brief

The 30-second read

$HSICBullishMed
01

Why it matters

The key tradable inputs are the reported Q2 revenue ($3.46B) and adjusted EPS ($1.27) versus consensus, plus the stated margin performance and the next-12-month revenue growth expectation (+2.9%).

02

Market read

This is a company-specific earnings beat story with immediate price reaction, but forward growth expectations appear only modest.

03

What to watch

Adjusted operating margin is described as down year over year (5.3% vs prior year), which could cap multiple expansion if investors focus on profitability trend rather than the beat.

Relevance 8/10Novelty 7/10Timing: reported Q2 CY2026 results, with immediate post-report stock move

Background

Henry Schein is a global distributor of dental and medical products and services, reporting Q2 CY2026 results with revenue and EPS beats.

Company-level read

Ticker impact

$HSICBullishMedium confidence
Context

Henry Schein reported Q2 CY2026 sales of $3.46B (+6.7% YoY) and adjusted EPS of $1.27, beating consensus and lifting the stock 1.5% to $87.79.

Expected impact

Likely supports continued upside bias versus estimates, but magnitude may be limited given only modest growth expectations for the next 12 months.

Evidence & confidence

The article provides concrete beat figures (revenue +2.6% vs estimates, EPS +2.5% vs consensus) and a same-day price reaction, but it also flags underwhelming forward revenue growth expectations (+2.9% over 12 months).

Market effects

Sector

Signals resilience in healthcare distribution demand and modest margin stability, relevant for dental/medical supply distributors.

Regional

No specific regional impact described beyond US-listed company results.

Global

Limited; article focuses on company-specific quarterly performance and guidance expectations.

Counterpoint

What could challenge this read

Forward revenue growth expectations of 2.9% over the next 12 months look soft, so the beat may not translate into sustained upside.

Key entities

  • company
    Henry Schein

    Reported Q2 CY2026 sales and adjusted EPS beats, with margin commentary and a modest same-day stock reaction.

Read at source← All news

Related articles

AUG 7
$HSICMed

Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution

Henry Schein Inc. outlined a transformation focused on AI, simpler leadership, and faster execution in its first earnings report under CEO Fred Lowery. The company reported Q2 net sales of $3.46B (+6.7%) and net income of $94M (+9.3%), raised its 2026 sales outlook to 4.5% to 5.5%, and announced a leadership reorganization integrating supply chain and distribution. It targets $200M+ operating improvements.

distributionstrategy.com7 min
AUG 6
$HSICMedAI 8/10

Henry Schein, Inc. Q2 2026 Earnings Call Summary

Henry Schein reported Q2 2026 progress including faster internal local-currency sales growth, driven by dental merchandise market-share gains and higher technology platform share. The company raised full-year 2026 sales growth guidance to 4.5% to 5.5% and expects $125 million operating income improvement run rate by end-2026. Restructuring expenses were $29 million.

yahoo.com6 min
AUG 4
$HSICHigh

HENRY SCHEIN INC (HSIC): Results of Operations and Financial Condition

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991.htm EX-99.1 exhibit991 -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS STRONG SECOND QUARTER 2026 FINANCIAL RESULTS AND RAISES FY2026 GUIDANCE ● Q2 2026 GAAP diluted EPS of $0.82 compared to $0.70 GAAP diluted EPS in Q2 2025 ● Q2 2026 non-GAAP diluted EPS

SEC EDGAR 8-K6 min
JUL 30
$HSICMed

Why is Henry Schein stock sliding today? By Investing.com

Henry Schein (HSIC) shares fell 1.8% to $84.25 after the company announced a leadership reorganization. Three senior executives, including COO Michael S. Ettinger, will leave effective Oct. 30, 2026, with a new leadership team and changes to supply chain and distribution. Investors are focused on execution ahead of Q2 results Aug. 4 and a $125 million operating income improvement target by year-end 2026.

investing.com3 min
MAY 30
$HSICMedAI 9/10

Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026

Henry Schein executives said underlying medical growth held up after Q1 pressure from respiratory-related diagnostic test kits, with medical growth at a mid-single-digit rate excluding that headwind, and continued into Q2. Dental demand was described as steady internationally (Germany, Canada). The company targets $125M net run-rate operating income improvement by end-2026 and up to $200M over the next few years, while prioritizing share repurchases and accelerating technology and specialty prod

finance.yahoo.com4 min